Proteomics and the future of diagnostics

What proteomics is

Genes are often described as the body's instruction manual, but genes mainly tell cells how to make proteins, and it is the proteins that actually carry out the work of life. They build tissues, carry oxygen, fight infection, send signals and control chemical reactions. Proteomics is the large-scale study of all the proteins in a cell, tissue or sample of blood — collectively called the proteome. Unlike our genes, which stay largely the same throughout life, the proteome is constantly changing in response to age, diet, activity, stress and disease. This makes it a rich, up-to-the-minute picture of what is actually happening in the body right now. Where genetics can tell us what might happen, proteomics can help show what is happening. That real-time quality is exactly what makes it so promising for diagnosis.

How proteins are measured

Measuring proteins is harder than reading genes, because there are far more of them and their amounts vary enormously. Two main approaches are used. The first, called mass spectrometry, works a bit like a very precise set of scales, sorting and weighing the fragments of proteins in a sample to identify and count them. The second uses specially designed molecules that latch onto particular target proteins, allowing thousands to be measured at once on a small chip or platform. Advances in both methods, combined with powerful computing and artificial intelligence to make sense of the huge amounts of data, mean scientists can now measure thousands of proteins from a single drop of blood. Just as importantly, the tests are becoming faster and cheaper, which is essential if they are ever to be used widely in everyday healthcare rather than only in research laboratories.

Spotting disease earlier

One of the most exciting hopes for proteomics is earlier and more accurate diagnosis. Many diseases quietly change the mix of proteins in the blood long before symptoms appear. A pattern of proteins, sometimes called a protein signature, may act as an early warning sign — for example, hinting at a cancer while it is still small and more treatable, or flagging heart or kidney trouble before it causes obvious problems. Because a single blood test could screen for a protein signature covering several conditions at once, proteomics might one day allow broad, gentle health checks from a simple sample. Researchers are also using protein patterns to predict who is most at risk of developing a disease in the coming years, which could allow prevention to start earlier. Turning these promising signals into reliable, everyday tests is now a major focus of research.

Personalising treatment

Beyond spotting disease, proteomics could help doctors choose the right treatment for the right person, an idea often called personalised or precision medicine. Two people with what looks like the same illness can respond very differently to the same drug. Because proteins reflect how a disease is actually behaving in an individual, protein patterns may help predict who will benefit from a particular treatment and who might suffer side effects, sparing people from medicines unlikely to work for them. Protein measurements can also help track whether a treatment is working, by showing whether the disease signature is settling down. In some cancers and immune conditions, tests based on proteins already guide treatment choices. As proteomics matures, this kind of tailored care — matching therapy to a person's own biology rather than treating everyone the same — could become far more common across many conditions.

Challenges and what comes next

Despite the excitement, several hurdles remain before proteomics becomes routine. The proteome is complex and varies naturally between people and even within the same person from day to day, so telling a meaningful change from normal variation is difficult. Tests must be proven to be accurate, reliable and genuinely useful before they can be trusted for real decisions, and this requires large, careful studies in diverse groups of people. There are practical questions too: cost, standardising results between laboratories, and making sure a positive test leads to helpful action rather than unnecessary worry or over-treatment. Handling large amounts of personal health data raises privacy considerations that must be managed responsibly. In the UK, researchers, the NHS and regulators are working to evaluate these tests rigorously. If those challenges are met, proteomics could become a powerful everyday tool for earlier, more personalised care.